1450881-55-6
1450881-55-6 structure
- Name: SAR-20347
- Chemical Name: SAR-20347
- CAS Number: 1450881-55-6
- Molecular Formula: C21H18ClFN4O4
- Molecular Weight: 444.843
- Catalog: Research Areas Cancer
- Create Date: 2018-02-17 18:07:57
- Modify Date: 2024-01-12 11:52:12
-
SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50s of 0.6, 23, 26 and 41 nM, respectively.
| Name | SAR-20347 |
|---|---|
| Synonyms |
2-(2-Chloro-6-fluorophenyl)-5-{[4-(4-morpholinylcarbonyl)phenyl]amino}-1,3-oxazole-4-carboxamide
MFCD28502117 4-Oxazolecarboxamide, 2-(2-chloro-6-fluorophenyl)-5-[[4-(4-morpholinylcarbonyl)phenyl]amino]- |
| Description | SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50s of 0.6, 23, 26 and 41 nM, respectively. |
|---|---|
| Related Catalog | |
| Target |
Tyk2:0.6 nM (IC50) JAK1:23 nM (IC50) JAK2:26 nM (IC50) JAK3:41 nM (IC50) |
| In Vitro | When NK-92 cells are stimulated with IL-12, SAR-20347 potently inhibits IL-12-mediated STAT4 phosphorylation, a TYK2-dependent event, with an IC50 of 126 nM. SAR-20347 demonstrates a selectivity of TYK2>JAK1>JAK2>JAK3. Cells without IL-12 in the culture media have no measureable IFN-γ, while cells incubated with IL-12 and SAR-20347 demonstrate dose-dependent inhibition of IFN-γ production. SAR-20347 dose-dependently inhibits the production of secreted embryonic alkaline phosphatase (SEAP) with greatest inhibition occurring with 5 μM of SAR-20347 in these experiments[1]. |
| In Vivo | 60 mg/kg SAR-20347 inhibits the production of IFN-γ in the serum by 91% compare to vehicle-treated animals, demonstrating that SAR-20347 can inhibit TYK2 signaling in vivo. SAR-20347 treatment significantly reduces IL-17 production as measured by average signal intensity, consistent with the gene expression analysis[1]. |
| Kinase Assay | Kinases are prepared in Base Reaction Buffer (20 mM Hepes pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO) and substrate is added with 1.5 mM CaCl2, 16 μg/mL Calmodulin, and 2 mM MnCl2. Varying concentrations of SAR-20347 in DMSO are added to the kinase reaction along with 10 μM 33P-ATP (activity 0.01 μCi/μL final) for IC50 determination[1]. |
| Cell Assay | Cells are plated in a 96-well v-bottom plate in starvation medium, incubated with SAR-20347 (0.5% DMSO) for 20 minutes at 37°C, 5% CO2, and stimulated with individual cytokines. P-STAT levels are measured in duplicate using MSD plates following the manufacturer's instructions (MSD). The IC50 is determined by subtracting background (no cytokine) and relative to DMSO/cytokine control[1]. |
| Animal Admin | Female 7 to 9 week old C57BL/6 mice are used. Mice are administered vehicle or 50 mg/kg SAR-20347 by oral gavage 30 minutes prior to application of 62.5 mg 5% imiquimod cream or control cream. Another dose of vehicle or 50 mg/kg SAR-20347 is given 5.5 hours following the first dose. This treatment is repeated for 5 days and on day 3 and 4, animals are injected with 100 uL saline to prevent dehydration. Each day, the mice are assessed by the same researcher for redness. On the 6th day, the animals are euthanized and photographs are taken[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 698.3±65.0 °C at 760 mmHg |
| Molecular Formula | C21H18ClFN4O4 |
| Molecular Weight | 444.843 |
| Flash Point | 376.1±34.3 °C |
| Exact Mass | 444.100067 |
| LogP | 0.22 |
| Vapour Pressure | 0.0±2.2 mmHg at 25°C |
| Index of Refraction | 1.644 |
| Storage condition | 2-8℃ |